Short Interest in Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Expands By 76.1%

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) was the target of a significant growth in short interest during the month of May. As of May 29th, there was short interest totaling 13,903 shares, a growth of 76.1% from the May 14th total of 7,893 shares. Based on an average daily volume of 24,005 shares, the days-to-cover ratio is currently 0.6 days. Approximately 0.1% of the company’s shares are short sold.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings cut Alaunos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 29th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has a consensus rating of “Sell”.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Alaunos Therapeutics stock. HRT Financial LP bought a new stake in Alaunos Therapeutics, Inc. (NASDAQ:TCRT) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 12,602 shares of the company’s stock, valued at approximately $40,000. HRT Financial LP owned about 0.54% of Alaunos Therapeutics at the end of the most recent quarter. 27.72% of the stock is owned by institutional investors and hedge funds.

Alaunos Therapeutics Stock Performance

Alaunos Therapeutics stock traded up $0.02 during midday trading on Monday, reaching $2.28. The stock had a trading volume of 10,993 shares, compared to its average volume of 18,571. Alaunos Therapeutics has a twelve month low of $1.67 and a twelve month high of $6.20. The stock has a market capitalization of $55.68 million, a PE ratio of -1.07 and a beta of -1.07. The stock’s 50-day simple moving average is $2.63 and its 200 day simple moving average is $2.99.

Alaunos Therapeutics (NASDAQ:TCRT) last issued its earnings results on Friday, May 15th. The company reported ($0.59) earnings per share for the quarter.

Alaunos Therapeutics Company Profile

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology.